nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—Mitomycin—urinary bladder cancer	0.126	0.324	CbGbCtD
Nefazodone—CYP3A4—Thiotepa—urinary bladder cancer	0.0573	0.147	CbGbCtD
Nefazodone—ADRA1B—vas deferens—urinary bladder cancer	0.0561	0.473	CbGeAlD
Nefazodone—CYP3A5—Etoposide—urinary bladder cancer	0.0398	0.102	CbGbCtD
Nefazodone—ABCB1—Gemcitabine—urinary bladder cancer	0.0363	0.0932	CbGbCtD
Nefazodone—ABCB1—Cisplatin—urinary bladder cancer	0.0264	0.0677	CbGbCtD
Nefazodone—ABCB1—Etoposide—urinary bladder cancer	0.0259	0.0666	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—urinary bladder cancer	0.0177	0.0454	CbGbCtD
Nefazodone—ABCB1—Methotrexate—urinary bladder cancer	0.0171	0.044	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—urinary bladder cancer	0.0167	0.0428	CbGbCtD
Nefazodone—CYP3A4—Etoposide—urinary bladder cancer	0.0155	0.0399	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—urinary bladder cancer	0.0106	0.0272	CbGbCtD
Nefazodone—HTR2A—urine—urinary bladder cancer	0.00507	0.0427	CbGeAlD
Nefazodone—CYP3A4—urine—urinary bladder cancer	0.00469	0.0396	CbGeAlD
Nefazodone—CYP2D6—urine—urinary bladder cancer	0.00461	0.0389	CbGeAlD
Nefazodone—ADRA1B—renal system—urinary bladder cancer	0.00341	0.0288	CbGeAlD
Nefazodone—ADRA1A—prostate gland—urinary bladder cancer	0.00281	0.0237	CbGeAlD
Nefazodone—CYP3A5—prostate gland—urinary bladder cancer	0.00224	0.0189	CbGeAlD
Nefazodone—ADRA2A—prostate gland—urinary bladder cancer	0.00214	0.018	CbGeAlD
Nefazodone—HTR1A—renal system—urinary bladder cancer	0.00208	0.0175	CbGeAlD
Nefazodone—ADRA1A—epithelium—urinary bladder cancer	0.00207	0.0174	CbGeAlD
Nefazodone—HTR2C—female reproductive system—urinary bladder cancer	0.00198	0.0167	CbGeAlD
Nefazodone—ADRA1A—renal system—urinary bladder cancer	0.00192	0.0162	CbGeAlD
Nefazodone—SLC6A4—female reproductive system—urinary bladder cancer	0.00188	0.0158	CbGeAlD
Nefazodone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00181	0.0153	CbGeAlD
Nefazodone—SLC6A2—female reproductive system—urinary bladder cancer	0.00165	0.0139	CbGeAlD
Nefazodone—CYP3A5—renal system—urinary bladder cancer	0.00153	0.0129	CbGeAlD
Nefazodone—ADRA2A—urethra—urinary bladder cancer	0.00143	0.0121	CbGeAlD
Nefazodone—HTR2A—epithelium—urinary bladder cancer	0.00134	0.0113	CbGeAlD
Nefazodone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00129	0.0109	CbGeAlD
Nefazodone—HTR2A—renal system—urinary bladder cancer	0.00124	0.0105	CbGeAlD
Nefazodone—ABCB1—prostate gland—urinary bladder cancer	0.00119	0.0101	CbGeAlD
Nefazodone—ADRA2A—female reproductive system—urinary bladder cancer	0.00117	0.00985	CbGeAlD
Nefazodone—CYP3A4—renal system—urinary bladder cancer	0.00115	0.00968	CbGeAlD
Nefazodone—CYP2D6—renal system—urinary bladder cancer	0.00113	0.00953	CbGeAlD
Nefazodone—CYP3A5—vagina—urinary bladder cancer	0.00111	0.00934	CbGeAlD
Nefazodone—ADRA2A—vagina—urinary bladder cancer	0.00106	0.00891	CbGeAlD
Nefazodone—ABCB1—seminal vesicle—urinary bladder cancer	0.00101	0.0085	CbGeAlD
Nefazodone—HTR2A—female reproductive system—urinary bladder cancer	0.000993	0.00838	CbGeAlD
Nefazodone—SLC6A2—lymph node—urinary bladder cancer	0.000966	0.00815	CbGeAlD
Nefazodone—CYP3A4—female reproductive system—urinary bladder cancer	0.000919	0.00775	CbGeAlD
Nefazodone—CYP2D6—female reproductive system—urinary bladder cancer	0.000904	0.00763	CbGeAlD
Nefazodone—HTR2A—vagina—urinary bladder cancer	0.000898	0.00757	CbGeAlD
Nefazodone—ABCB1—epithelium—urinary bladder cancer	0.000876	0.00739	CbGeAlD
Nefazodone—ABCB1—renal system—urinary bladder cancer	0.000812	0.00685	CbGeAlD
Nefazodone—ABCB1—urethra—urinary bladder cancer	0.000798	0.00673	CbGeAlD
Nefazodone—ADRA2A—lymph node—urinary bladder cancer	0.000683	0.00576	CbGeAlD
Nefazodone—ABCB1—female reproductive system—urinary bladder cancer	0.00065	0.00549	CbGeAlD
Nefazodone—ABCB1—vagina—urinary bladder cancer	0.000588	0.00496	CbGeAlD
Nefazodone—ABCB1—lymph node—urinary bladder cancer	0.00038	0.00321	CbGeAlD
Nefazodone—Haemorrhage—Methotrexate—urinary bladder cancer	0.000278	0.000683	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—urinary bladder cancer	0.000278	0.000683	CcSEcCtD
Nefazodone—Sweating—Epirubicin—urinary bladder cancer	0.000278	0.000682	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000278	0.000682	CcSEcCtD
Nefazodone—Asthenia—Gemcitabine—urinary bladder cancer	0.000277	0.00068	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—urinary bladder cancer	0.000276	0.000679	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—urinary bladder cancer	0.000276	0.000678	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000274	0.000674	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—urinary bladder cancer	0.000274	0.000672	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—urinary bladder cancer	0.000273	0.000671	CcSEcCtD
Nefazodone—Pruritus—Gemcitabine—urinary bladder cancer	0.000273	0.000671	CcSEcCtD
Nefazodone—Nausea—Thiotepa—urinary bladder cancer	0.000273	0.00067	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—urinary bladder cancer	0.000272	0.000668	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—urinary bladder cancer	0.000272	0.000668	CcSEcCtD
Nefazodone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000272	0.000667	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—urinary bladder cancer	0.00027	0.000662	CcSEcCtD
Nefazodone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00027	0.000662	CcSEcCtD
Nefazodone—Pruritus—Fluorouracil—urinary bladder cancer	0.000269	0.00066	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—urinary bladder cancer	0.000268	0.000658	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000266	0.000653	CcSEcCtD
Nefazodone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000265	0.000651	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—urinary bladder cancer	0.000265	0.00065	CcSEcCtD
Nefazodone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000264	0.000649	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000263	0.000646	CcSEcCtD
Nefazodone—Urticaria—Etoposide—urinary bladder cancer	0.000262	0.000643	CcSEcCtD
Nefazodone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000261	0.000642	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—urinary bladder cancer	0.000261	0.000642	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—urinary bladder cancer	0.000261	0.000641	CcSEcCtD
Nefazodone—Abdominal pain—Etoposide—urinary bladder cancer	0.000261	0.00064	CcSEcCtD
Nefazodone—Body temperature increased—Etoposide—urinary bladder cancer	0.000261	0.00064	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000261	0.00064	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000261	0.00064	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—urinary bladder cancer	0.00026	0.000639	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—urinary bladder cancer	0.00026	0.000639	CcSEcCtD
Nefazodone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00026	0.000638	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—urinary bladder cancer	0.000259	0.000637	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000259	0.000636	CcSEcCtD
Nefazodone—Asthenia—Cisplatin—urinary bladder cancer	0.000258	0.000634	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000258	0.000634	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—urinary bladder cancer	0.000257	0.000631	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000256	0.000629	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—urinary bladder cancer	0.000256	0.000628	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000253	0.000621	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000252	0.000618	CcSEcCtD
Nefazodone—Dizziness—Fluorouracil—urinary bladder cancer	0.000251	0.000617	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—urinary bladder cancer	0.000251	0.000616	CcSEcCtD
Nefazodone—Chills—Methotrexate—urinary bladder cancer	0.000249	0.000613	CcSEcCtD
Nefazodone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000246	0.000605	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000246	0.000604	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—urinary bladder cancer	0.000246	0.000603	CcSEcCtD
Nefazodone—Vomiting—Gemcitabine—urinary bladder cancer	0.000245	0.000603	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000245	0.000602	CcSEcCtD
Nefazodone—Rash—Gemcitabine—urinary bladder cancer	0.000243	0.000598	CcSEcCtD
Nefazodone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000243	0.000597	CcSEcCtD
Nefazodone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000243	0.000597	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—urinary bladder cancer	0.000243	0.000596	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000242	0.000594	CcSEcCtD
Nefazodone—Headache—Gemcitabine—urinary bladder cancer	0.000242	0.000594	CcSEcCtD
Nefazodone—Flushing—Epirubicin—urinary bladder cancer	0.000241	0.000593	CcSEcCtD
Nefazodone—Vomiting—Fluorouracil—urinary bladder cancer	0.000241	0.000593	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000241	0.000593	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000241	0.000591	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000241	0.000591	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000239	0.000588	CcSEcCtD
Nefazodone—Rash—Fluorouracil—urinary bladder cancer	0.000239	0.000588	CcSEcCtD
Nefazodone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000239	0.000587	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000239	0.000587	CcSEcCtD
Nefazodone—Headache—Fluorouracil—urinary bladder cancer	0.000238	0.000584	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000237	0.000582	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000237	0.000582	CcSEcCtD
Nefazodone—Asthenia—Etoposide—urinary bladder cancer	0.000237	0.000581	CcSEcCtD
Nefazodone—Back pain—Methotrexate—urinary bladder cancer	0.000234	0.000575	CcSEcCtD
Nefazodone—Chills—Epirubicin—urinary bladder cancer	0.000233	0.000573	CcSEcCtD
Nefazodone—Pruritus—Etoposide—urinary bladder cancer	0.000233	0.000573	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000232	0.00057	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—urinary bladder cancer	0.00023	0.000565	CcSEcCtD
Nefazodone—Nausea—Gemcitabine—urinary bladder cancer	0.000229	0.000563	CcSEcCtD
Nefazodone—Vomiting—Cisplatin—urinary bladder cancer	0.000229	0.000562	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—urinary bladder cancer	0.000228	0.00056	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000228	0.000559	CcSEcCtD
Nefazodone—Rash—Cisplatin—urinary bladder cancer	0.000227	0.000557	CcSEcCtD
Nefazodone—Dermatitis—Cisplatin—urinary bladder cancer	0.000227	0.000557	CcSEcCtD
Nefazodone—Diarrhoea—Etoposide—urinary bladder cancer	0.000226	0.000554	CcSEcCtD
Nefazodone—Nausea—Fluorouracil—urinary bladder cancer	0.000225	0.000554	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000224	0.000551	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000224	0.000551	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—urinary bladder cancer	0.000224	0.000549	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—urinary bladder cancer	0.000223	0.000549	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—urinary bladder cancer	0.000223	0.000548	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000222	0.000545	CcSEcCtD
Nefazodone—Back pain—Epirubicin—urinary bladder cancer	0.000219	0.000538	CcSEcCtD
Nefazodone—Malaise—Methotrexate—urinary bladder cancer	0.000218	0.000536	CcSEcCtD
Nefazodone—Dizziness—Etoposide—urinary bladder cancer	0.000218	0.000536	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000218	0.000535	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—urinary bladder cancer	0.000217	0.000534	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—urinary bladder cancer	0.000217	0.000532	CcSEcCtD
Nefazodone—Chills—Doxorubicin—urinary bladder cancer	0.000216	0.00053	CcSEcCtD
Nefazodone—Nausea—Cisplatin—urinary bladder cancer	0.000214	0.000525	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—urinary bladder cancer	0.000213	0.000524	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—urinary bladder cancer	0.000213	0.000522	CcSEcCtD
Nefazodone—Cough—Methotrexate—urinary bladder cancer	0.000211	0.000519	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00021	0.000516	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—urinary bladder cancer	0.00021	0.000515	CcSEcCtD
Nefazodone—Vomiting—Etoposide—urinary bladder cancer	0.00021	0.000515	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—urinary bladder cancer	0.000209	0.000514	CcSEcCtD
Nefazodone—Agitation—Epirubicin—urinary bladder cancer	0.000208	0.000511	CcSEcCtD
Nefazodone—Rash—Etoposide—urinary bladder cancer	0.000208	0.000511	CcSEcCtD
Nefazodone—Dermatitis—Etoposide—urinary bladder cancer	0.000208	0.00051	CcSEcCtD
Nefazodone—Headache—Etoposide—urinary bladder cancer	0.000207	0.000507	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—urinary bladder cancer	0.000206	0.000507	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—urinary bladder cancer	0.000206	0.000506	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—urinary bladder cancer	0.000206	0.000506	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—urinary bladder cancer	0.000206	0.000506	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000205	0.000504	CcSEcCtD
Nefazodone—Malaise—Epirubicin—urinary bladder cancer	0.000204	0.000502	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—urinary bladder cancer	0.000204	0.0005	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—urinary bladder cancer	0.000203	0.0005	CcSEcCtD
Nefazodone—Syncope—Epirubicin—urinary bladder cancer	0.000203	0.000499	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—urinary bladder cancer	0.000203	0.000498	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—urinary bladder cancer	0.000203	0.000498	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000201	0.000495	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—urinary bladder cancer	0.0002	0.000492	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—urinary bladder cancer	0.000199	0.000489	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000199	0.000489	CcSEcCtD
Nefazodone—Cough—Epirubicin—urinary bladder cancer	0.000198	0.000485	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000197	0.000485	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000197	0.000485	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—urinary bladder cancer	0.000196	0.000482	CcSEcCtD
Nefazodone—Infection—Methotrexate—urinary bladder cancer	0.000196	0.000482	CcSEcCtD
Nefazodone—Nausea—Etoposide—urinary bladder cancer	0.000196	0.000481	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—urinary bladder cancer	0.000195	0.00048	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000194	0.000478	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—urinary bladder cancer	0.000194	0.000476	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000193	0.000475	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—urinary bladder cancer	0.000193	0.000474	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—urinary bladder cancer	0.000193	0.000474	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—urinary bladder cancer	0.000193	0.000474	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—urinary bladder cancer	0.000193	0.000473	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—urinary bladder cancer	0.000192	0.000472	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000191	0.000469	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—urinary bladder cancer	0.00019	0.000468	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—urinary bladder cancer	0.000189	0.000464	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—urinary bladder cancer	0.000189	0.000463	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—urinary bladder cancer	0.000188	0.000462	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—urinary bladder cancer	0.000188	0.000462	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—urinary bladder cancer	0.000188	0.000462	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000188	0.000461	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—urinary bladder cancer	0.000186	0.000458	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—urinary bladder cancer	0.000185	0.000455	CcSEcCtD
Nefazodone—Oedema—Epirubicin—urinary bladder cancer	0.000185	0.000454	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000185	0.000454	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—urinary bladder cancer	0.000185	0.000453	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000184	0.000452	CcSEcCtD
Nefazodone—Infection—Epirubicin—urinary bladder cancer	0.000184	0.000451	CcSEcCtD
Nefazodone—Cough—Doxorubicin—urinary bladder cancer	0.000183	0.000449	CcSEcCtD
Nefazodone—Shock—Epirubicin—urinary bladder cancer	0.000182	0.000447	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—urinary bladder cancer	0.000182	0.000446	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000181	0.000444	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—urinary bladder cancer	0.000181	0.000444	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—urinary bladder cancer	0.00018	0.000443	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00018	0.000442	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000179	0.000439	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—urinary bladder cancer	0.000179	0.000439	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—urinary bladder cancer	0.000178	0.000438	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000178	0.000438	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—urinary bladder cancer	0.000178	0.000438	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—urinary bladder cancer	0.000178	0.000437	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000177	0.000436	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—urinary bladder cancer	0.000176	0.000433	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—urinary bladder cancer	0.000176	0.000433	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000176	0.000432	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—urinary bladder cancer	0.000176	0.000431	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000174	0.000429	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000174	0.000427	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—urinary bladder cancer	0.000173	0.000424	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—urinary bladder cancer	0.000172	0.000424	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000172	0.000422	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000171	0.00042	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—urinary bladder cancer	0.000171	0.00042	CcSEcCtD
Nefazodone—Infection—Doxorubicin—urinary bladder cancer	0.00017	0.000417	CcSEcCtD
Nefazodone—Pain—Methotrexate—urinary bladder cancer	0.000169	0.000415	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000168	0.000414	CcSEcCtD
Nefazodone—Shock—Doxorubicin—urinary bladder cancer	0.000168	0.000413	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000167	0.000411	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—urinary bladder cancer	0.000167	0.000411	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000167	0.00041	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000166	0.000408	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000165	0.000406	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000165	0.000405	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—urinary bladder cancer	0.000164	0.000404	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—urinary bladder cancer	0.000163	0.0004	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000163	0.0004	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000163	0.0004	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000161	0.000397	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000161	0.000395	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—urinary bladder cancer	0.00016	0.000392	CcSEcCtD
Nefazodone—Constipation—Epirubicin—urinary bladder cancer	0.000158	0.000388	CcSEcCtD
Nefazodone—Pain—Epirubicin—urinary bladder cancer	0.000158	0.000388	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—urinary bladder cancer	0.000157	0.000385	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000156	0.000383	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000156	0.000383	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000156	0.000383	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—urinary bladder cancer	0.000155	0.00038	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000154	0.000377	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000152	0.000374	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000152	0.000374	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—urinary bladder cancer	0.000152	0.000373	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000151	0.000371	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000151	0.00037	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000149	0.000365	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—urinary bladder cancer	0.000147	0.000361	CcSEcCtD
Nefazodone—Pain—Doxorubicin—urinary bladder cancer	0.000146	0.000359	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—urinary bladder cancer	0.000146	0.000359	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000146	0.000359	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000146	0.000359	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000145	0.000357	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—urinary bladder cancer	0.000142	0.000348	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000141	0.000346	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00014	0.000343	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—urinary bladder cancer	0.00014	0.000343	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000136	0.000334	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—urinary bladder cancer	0.000136	0.000334	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000135	0.000332	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000135	0.000332	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000135	0.000332	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—urinary bladder cancer	0.000133	0.000326	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—urinary bladder cancer	0.000131	0.000321	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—urinary bladder cancer	0.000131	0.000321	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000126	0.000311	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000126	0.000309	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—urinary bladder cancer	0.000126	0.000308	CcSEcCtD
Nefazodone—Rash—Methotrexate—urinary bladder cancer	0.000125	0.000306	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—urinary bladder cancer	0.000124	0.000306	CcSEcCtD
Nefazodone—Headache—Methotrexate—urinary bladder cancer	0.000124	0.000304	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—urinary bladder cancer	0.000123	0.000301	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—urinary bladder cancer	0.000122	0.0003	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—urinary bladder cancer	0.000121	0.000297	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—urinary bladder cancer	0.000117	0.000289	CcSEcCtD
Nefazodone—Nausea—Methotrexate—urinary bladder cancer	0.000117	0.000288	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000117	0.000287	CcSEcCtD
Nefazodone—Rash—Epirubicin—urinary bladder cancer	0.000117	0.000286	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—urinary bladder cancer	0.000116	0.000286	CcSEcCtD
Nefazodone—Headache—Epirubicin—urinary bladder cancer	0.000116	0.000284	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—urinary bladder cancer	0.000113	0.000278	CcSEcCtD
Nefazodone—Nausea—Epirubicin—urinary bladder cancer	0.00011	0.00027	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—urinary bladder cancer	0.000109	0.000267	CcSEcCtD
Nefazodone—Rash—Doxorubicin—urinary bladder cancer	0.000108	0.000265	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000108	0.000265	CcSEcCtD
Nefazodone—Headache—Doxorubicin—urinary bladder cancer	0.000107	0.000263	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—urinary bladder cancer	0.000102	0.000249	CcSEcCtD
Nefazodone—ADRA1A—GPCR downstream signaling—RHOA—urinary bladder cancer	2.03e-05	0.000239	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	2.01e-05	0.000237	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.01e-05	0.000236	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	2e-05	0.000235	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.99e-05	0.000234	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—S100B—urinary bladder cancer	1.99e-05	0.000233	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.97e-05	0.000232	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NCOR1—urinary bladder cancer	1.97e-05	0.000231	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—TYMS—urinary bladder cancer	1.96e-05	0.000231	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—S100B—urinary bladder cancer	1.94e-05	0.000228	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NCOR1—urinary bladder cancer	1.94e-05	0.000228	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTM1—urinary bladder cancer	1.94e-05	0.000228	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.94e-05	0.000228	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—IL2—urinary bladder cancer	1.92e-05	0.000225	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.91e-05	0.000225	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	1.9e-05	0.000224	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	1.89e-05	0.000222	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RHOA—urinary bladder cancer	1.88e-05	0.000221	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GPX1—urinary bladder cancer	1.86e-05	0.000219	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.85e-05	0.000218	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RHOA—urinary bladder cancer	1.84e-05	0.000217	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	1.83e-05	0.000215	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	1.83e-05	0.000215	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CXCL8—urinary bladder cancer	1.82e-05	0.000214	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	1.82e-05	0.000214	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.82e-05	0.000214	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	1.82e-05	0.000214	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	1.81e-05	0.000213	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	1.81e-05	0.000213	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	1.81e-05	0.000212	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.8e-05	0.000212	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	1.78e-05	0.00021	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.78e-05	0.000209	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.78e-05	0.000209	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.78e-05	0.000209	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.76e-05	0.000207	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.75e-05	0.000206	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NCOR1—urinary bladder cancer	1.75e-05	0.000205	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL2—urinary bladder cancer	1.74e-05	0.000205	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	1.74e-05	0.000204	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TERT—urinary bladder cancer	1.73e-05	0.000204	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	1.72e-05	0.000202	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	1.71e-05	0.000201	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.7e-05	0.0002	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	1.7e-05	0.0002	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.69e-05	0.000199	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.68e-05	0.000197	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.67e-05	0.000197	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.67e-05	0.000196	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	1.66e-05	0.000195	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.66e-05	0.000195	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.65e-05	0.000194	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000194	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	1.62e-05	0.000191	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	1.62e-05	0.000191	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.62e-05	0.00019	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	1.61e-05	0.00019	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—urinary bladder cancer	1.61e-05	0.000189	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	1.59e-05	0.000187	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	1.58e-05	0.000186	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	1.58e-05	0.000186	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	1.57e-05	0.000185	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.57e-05	0.000185	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	1.55e-05	0.000182	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	1.55e-05	0.000182	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	1.54e-05	0.000181	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	1.54e-05	0.000181	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.5e-05	0.000177	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.46e-05	0.000172	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.45e-05	0.00017	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.44e-05	0.00017	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	1.44e-05	0.000169	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	1.43e-05	0.000168	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.42e-05	0.000167	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	1.42e-05	0.000166	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.41e-05	0.000166	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	1.4e-05	0.000165	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	1.4e-05	0.000165	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.4e-05	0.000164	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	1.4e-05	0.000164	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—urinary bladder cancer	1.39e-05	0.000164	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	1.39e-05	0.000163	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.39e-05	0.000163	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000162	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	1.37e-05	0.000161	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.36e-05	0.00016	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	1.35e-05	0.000159	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.34e-05	0.000158	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.34e-05	0.000158	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.34e-05	0.000157	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.34e-05	0.000157	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	1.34e-05	0.000157	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	1.34e-05	0.000157	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	1.33e-05	0.000156	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.32e-05	0.000155	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.31e-05	0.000154	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.31e-05	0.000154	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.3e-05	0.000153	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.29e-05	0.000151	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.29e-05	0.000151	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.00015	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.28e-05	0.00015	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.28e-05	0.00015	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.28e-05	0.00015	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000149	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000149	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.26e-05	0.000148	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	1.26e-05	0.000148	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.23e-05	0.000144	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	1.23e-05	0.000144	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.23e-05	0.000144	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.21e-05	0.000143	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000142	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.21e-05	0.000142	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.21e-05	0.000142	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.2e-05	0.000141	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.19e-05	0.00014	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.00014	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	1.19e-05	0.00014	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.19e-05	0.00014	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.19e-05	0.000139	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.18e-05	0.000139	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.15e-05	0.000136	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.14e-05	0.000134	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	1.13e-05	0.000133	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.13e-05	0.000133	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.12e-05	0.000132	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.12e-05	0.000132	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.000131	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.12e-05	0.000131	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.12e-05	0.000131	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.12e-05	0.000131	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	1.11e-05	0.000131	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.1e-05	0.00013	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.1e-05	0.000129	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	1.09e-05	0.000129	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.09e-05	0.000128	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.08e-05	0.000127	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.08e-05	0.000127	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.08e-05	0.000126	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.07e-05	0.000126	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.07e-05	0.000126	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.05e-05	0.000124	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.05e-05	0.000123	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.04e-05	0.000122	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.03e-05	0.000121	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.03e-05	0.000121	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.02e-05	0.00012	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.02e-05	0.00012	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.02e-05	0.000119	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.02e-05	0.000119	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.01e-05	0.000119	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.01e-05	0.000119	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.01e-05	0.000119	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.01e-05	0.000118	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1e-05	0.000118	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1e-05	0.000118	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	9.76e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	9.73e-06	0.000114	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	9.7e-06	0.000114	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	9.7e-06	0.000114	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	9.69e-06	0.000114	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	9.67e-06	0.000114	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	9.64e-06	0.000113	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—urinary bladder cancer	9.62e-06	0.000113	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	9.56e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—urinary bladder cancer	9.55e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	9.49e-06	0.000112	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	9.42e-06	0.000111	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	9.37e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	9.36e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	9.33e-06	0.00011	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	9.25e-06	0.000109	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	9.23e-06	0.000108	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	9.13e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—EP300—urinary bladder cancer	9.11e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	9.09e-06	0.000107	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.07e-06	0.000107	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	8.97e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	8.9e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	8.88e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	8.83e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	8.82e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.8e-06	0.000103	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	8.78e-06	0.000103	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	8.75e-06	0.000103	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.71e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	8.64e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.61e-06	0.000101	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	8.59e-06	0.000101	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	8.49e-06	9.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	8.44e-06	9.92e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	8.4e-06	9.87e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.37e-06	9.84e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	8.37e-06	9.84e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—EP300—urinary bladder cancer	8.34e-06	9.81e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.27e-06	9.73e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.27e-06	9.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	8.27e-06	9.72e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	8.26e-06	9.71e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	8.21e-06	9.66e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	8.19e-06	9.63e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	8.14e-06	9.57e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	8.04e-06	9.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	8.03e-06	9.44e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	8e-06	9.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	7.98e-06	9.38e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	7.97e-06	9.37e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.92e-06	9.31e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	7.86e-06	9.24e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	7.8e-06	9.17e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.78e-06	9.14e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	7.76e-06	9.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	7.61e-06	8.95e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	7.57e-06	8.9e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	7.43e-06	8.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	7.4e-06	8.7e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.31e-06	8.6e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	7.29e-06	8.57e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	7.14e-06	8.39e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.13e-06	8.39e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	7.13e-06	8.38e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	6.98e-06	8.21e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	6.93e-06	8.15e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	6.9e-06	8.11e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	6.74e-06	7.92e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	6.63e-06	7.8e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	6.63e-06	7.79e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.6e-06	7.76e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	6.6e-06	7.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	6.6e-06	7.76e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	6.6e-06	7.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	6.49e-06	7.63e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	6.31e-06	7.42e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—EP300—urinary bladder cancer	6.3e-06	7.4e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.22e-06	7.31e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	6.13e-06	7.21e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	5.99e-06	7.04e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.93e-06	6.97e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.93e-06	6.97e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	5.86e-06	6.89e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	5.73e-06	6.73e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.7e-06	6.7e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	5.61e-06	6.59e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	5.45e-06	6.4e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	5.21e-06	6.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.66e-06	5.48e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.07e-06	4.78e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.88e-06	4.56e-05	CbGpPWpGaD
